• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Auricula Biosciences

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

Auricula Biosciences

Investment: 2022
Visit Website

Auricula Biosciences is a project-focused company currently developing a first-in-class targeted therapeutic for a broad set of K-Ras mutant malignancies to clinical proof-of-concept. Ras mutation is the most frequent oncogenic alteration in human cancers and confers a poor prognosis as current targeted therapies are effective only in a minority of patients and hampered by the development of drug resistance. Auricula’s therapeutic candidate has been designed to bypass such resistance.

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact